INTRODUCTION
In kidney transplantation the presence of preexisting anti human leukocyte antigen (HLA) donor-specific antibodies (DSA) has impact on graft outcomes. Their presence is associated with an augmented risk of antibody-mediated rejection (AMR) [1] and worst graft survival [2] . Classically, antibodies against major HLA Class Ⅰ (A and B) and Class Ⅱ (DR and DQ) antigens are considered to be responsible for most cases of AMR. AntiHLA-Cw are considered less immunogenic when are paralleled to other class I antiHLA antibodies, mainly due to minor HLA-Cw antigen expression on cell surface [3] . Indeed, some studies found that the incidence of antiHLA-Cw antibodies in sensitized patients was lesser than that for HLA-A or HLA-B antibodies [4] [5] [6] . However, the progress of additional sensitive assays that identify HLA antibodies, namely solid-phase immunoassays, demonstrated that HLA-C locus may induce an antibody reaction comparable to the other usually tested loci [4, 5, 7, 8] . In 2012, Ling et al [5] showed that kidney transplantation in patients with isolated antiHLA-Cw antibodies was effective (no rejections occurred) when using induction treatment with anti-thymocyte globulin (ATG) and IVIG. Another study evaluated 22 patients with pretransplant DSA antiHLA-Cw in comparison with 88 patients allosensitized but with no detectable preformed DSA and concluded that they seem to be at superior risk for AMR occurrence [9] . Recently, Bachelet et al [10] in their retrospective and multicenter study showed that antiHLACw DSA have the same effect on graft outcome as DSA against "classical" HLA loci (A, B, DR, DQ), suggesting that antiHLA-Cw should also be considered in transplant allocation procedures and in immunologic risk stratification of patients. As this subject remains controversial, we decided to conduct a retrospective study in kidney transplant patients to investigate the clinical impact of preformed antiHLA-Cw DSA comparing them to DSA against the other HLA class I loci, namely antiHLA-A and/or B.
MATERIALS AND METHODS

Patients
From the database of our Histocompatibility Center 35 adults who received a kidney transplant since 2007 were identified as having pretransplant donor specific antibodies (DSA) exclusively antiHLA-A and/or -B or exclusively antiHLA-Cw. Twenty-three patients had DSA antiHLA-A and/or antiHLA-B: 6 with DSA antiHLA-A only; 11 with DSA antiHLA-B only and 6 with DSA antiHLA-A and -B. This group was designated DSA-A-B. Twelve patients had DSA exclusively antiHLA-Cw, and this group was designated DSA-Cw. The patients were all transplanted with a negative T-and B-cell cytotoxic crossmatch (standard NIH technique). The Institutional Review Board at Hospital Santo António, CHP approved this study.
AntiHLA antibody testing
Patients in the waiting list were examined for antiHLA IgG by multiplex microsphere based on Luminex Xmap ® Technology (LABScreen ® Mixed kit, OneLambda, Canoga Park, CA, United States). The cut-off for positive samples was the Normalized Background (NBG) ratio advocated by the manufacturer and executed by the HLA fusion ® software (One Lambda Inc.). To determinate the specificity of the HLA antibodies, single-antigen bead (SAB) assays (LabScreen Single Antigen Beads ® , OneLambda, Canoga Park, CA) were executed in patients with a positive screening, using the same pretransplant sera. The mean fluorescence intensity (MFI) was measured using LABScan ™ 100 flow analyzer (Luminex ® , Austin, TX, United States). The analysis was performed using HLA fusion ® software (One Lambda Inc.) and a cut-off for a positive reaction were set in MFI value of ≥ 1000.
Donor typing and crossmatch
Samples of all deceased donors were routinely typed before recipient selection in loci HLA-A*, B*, Cw* and DRB1* using polymerase chain reaction (PCR) amplification with specific sequence primers (SSP; Olerup SSP ® low resolution HLA typing kits, Stockholm, Sweden).
After donor HLA typing, using that information, a virtual crossmatch (virtual XM) was executed. Eight patients underwent a desensitization protocol. Five patients received intravenous immunoglobulin (IvIg) 2 g/kg at transplant (0.5 g/kg immediately before transplant, and at day 1, 2 and 3) and 1-mo after transplant (1 g/kg in 2 consecutive days). One patient received a similar dose of IvIg and underwent plasmapheresis every other day (first session immediately before transplant, for a total of 6-9 sessions) and two other patients received additionally a dose of Rituximab (375 mg/m 2 ) on day 3 post-transplant.
Patients' data and outcomes
The data concerning patients' characteristics and transplantation variables was collected retrospectively. Estimated glomerular filtration rate (eGFR) was assessed using the 2006 Modification of Diet in Renal Disease (MDRD) equation and dialysis requirement in the first week post-transplant was defined as delayed graft function. Patients were followed until graft failure, death or end of follow-up (five years after transplant or December 31, 2015, which came first). Graft survival was evaluated considering graft failure censored for death with a functioning graft.
Follow-up
Graft biopsies were performed "for cause" only. Allograft rejection was classified according Banff classification (updated in 2013) and defined by biopsy where specimens were evaluated by light microscopy and immunofluorescence (with C4d staining). Mild acute cellular rejection (ACR Banff grade Ⅰ) was treated with 500 mg methylprednisolone for 3 d and increased maintenance immunosuppression. All other ACR were treated with ATG. AMR patients were treated with plasmapheresis every other day (the number of plasmapheresis sessions was 4 per protocol) and IvIg 100 mg/kg after each session. After the last plasmapheresis session, they received a high-dose IvIg (2 g/kg) divided in four daily doses and the same dose was repeated 1 mo later. If not used at transplant, patients received, additionally, one dose of rituximab (375 mg/m 2 ).
Statistical analysis
Categorical data were expressed as numbers (frequencies) and continuous data were described using median (interquartile range). Categorical data (demographic and medical characteristics) were compared using Pearson χ
test or
Fisher's exact test, as appropriate. Continuous variables were compared with Mann-Whitney U test. Predictors of AMR were explored by univariate and multivariable (using a backward elimination method, with a P-value < 0.05 necessary for retention in the model) Cox regression. For graft survival curves was used the Kaplan-Meier method, and the comparison between groups was done by log-rank test.
RESULTS
Baseline characteristics
Baseline characteristics of DSA-Cw and DSA-A-B groups are given in Table 1 . DSA-Cw patients tended to be younger compared to patients in DSA-A-B group (respectively, 39 years vs 48 years), (P = 0.061). There was no significant difference between groups concerning gender, history of previous transplant or previous pregnancies. However DSA-Cw patients had significantly higher prevalence of previous blood transfusions (75% vs 39%, P = 0.044).
Concerning donor characteristics and pretransplant immunological data, namely donor age, donor gender, type of donor transplant (living vs decease), peak PRA, and DSA number, none of these characteristics significantly differed between groups. Although DSA strength median was higher in DSA-A-B (MFI 7583) in comparison with DSA-Cw group (MFI 2939), this difference was not rejection were diagnosed as AMR in the DSA-A-B group, while in the DSA-Cw group there were 2 cases of AMR and 1 of ACR. Figure 1 shows the incidence of AMR at one-year post-transplant, between DSA-A-B and DSA-Cw patients groups, (respectively, 26% and 17%, Log-rank P = 0.531) with no significant difference being detected. At one year, eGFR tended to be higher in DSA-Cw group (median 59 mL/min) compared to DSA-A-B group (median 51 mL/min), (P = 0.192) (Figure 2 ). Importantly, followup was significantly longer for the DSA-A-B group (median 60 mo) than in the DSA-Cw group (median 18 mo) (P < 0.001). Kidney graft survival at 5-years was also similar between groups (Figure 3 , 91% for the DSA-A-B group vs 100% for the DSA-Cw group, P = 0.528).
Antibody-mediated rejection: Incidence, predictors and clinical impact
AMR occurred in 8 patients (23%) of the overall cohort. Possible associations between clinical and immunological data and AMR incidence through a Cox regression analysis is shown in Table 3 . The sole independent predictor of AMR incidence was the DSA strength, both in uni-and multisignificant (P = 0.110).
Flow cytometry crossmatch (FCXM) was performed for 29 of 35 patients. Positive T-and/or B-cell FCXM was similarly uncommon between groups. Three (27%) patients had a positive T-cell FCXM in the DSA-Cw group and only one (6%) in the DSA-A-B group (P = 0.139). Only two patients had a positive B-cell FCXM and both belonged to the DSA-A-B group.
Immunosuppression and induction treatment were similar between groups. ATG induction was used in 14 (61%) and 9 (75%) patients from the DSA-A-B and DSA-Cw groups, respectively (P = 0.476). Additionally, 5 patients in the DSA-A-B group were desensitized: 2 of them using only IVIG, 1 with IVIG and plasmapheresis and another 2 combining IVIG, plasmapheresis and rituximab. In DSA-Cw group 3 patients were treated with IVIG.
Clinical outcomes
Transplant outcomes are detailed in Table 2 . There was no difference in terms of acute rejection at one year between the two groups (6 and 3 cases, respectively in the DSA-A-B and the DSA-Cw groups; P = 1). All cases of acute 
DISCUSSION
This retrospective study demonstrates that patients with preformed DSA solely antiHLA-Cw had a similar impact on post-transplant outcomes comparing to those patients with preformed antiHLA-A/-B DSA. Both groups had a relative high incidence of AMR at one year, 26% in the DSA-A-B group and 25% in DSA-Cw group. Also, the impact on graft outcomes measured by eGFR at one-year and graft survival at the end of follow-up was comparable between groups. HLA-Cw molecules are scantily expressed at the cell surface compared with HLA-A and HLA-B locus products, but intracellular HLA-A, HLA-B and HLA-Cw alleles are expressed in similar quantities [3, 11] . One reason pointed for this low amount at the cell surface is the fact that HLA-Cw alleles interact in a very stable way with the transporter associated with antigen processing (TAP) and they are kept in the endoplasmic reticulum, where they are degraded [11] . Another justification for finding low HLACw at cell proposed by McCutcheon et al [3] is that HLACw heavy chain mRNA is instable and rapidly degraded, resulting in a lower rate of protein. This fact, associated with the modest sensitivity of the lymphocytotocicitybased assays used in the past for identification of HLACw antigens, probably explains why for many years they were considered less immunogenic and neglected in the matching systems of most kidney allocation procedures. Recent studies confirm their lower frequency. Bryan et al [6] in 2010 described in their sensitized transplant patients a 42% positivity to HLA-Cw, which was significantly lesser than sensitization to HLA-A (80%) and HLA-B (83%). In 2012, Ling et al [5] , obtained similar results and showed that the frequency of antiHLACw antibodies in sensitized patients was about 56%, lower than HLA-A (79%) and B (86%) antibodies. Our group evaluated 453 sensitized kidney transplantation candidates to determine the presence of antiHLA class Ⅰ and class Ⅱ antibodies, comparing how different sensitization events, such as pregnancy, transfusion or previous organ transplantation, affected the degree of HLA alloimmunization [12] . For antiHLA antibodies against class Ⅰ, if the sensitization event was previous transplant only, the antiHLA antibodies prevalence was 21.2% for -A, 28.8% for -B and 21.1% for -Cw; if the single sensitization event was previous transfusion, the antiHLA antibodies prevalence was 3.9% for -A, 5.5% for -B and 1.6% for -Cw. At last, if the sensitization event was pregnancy only, the antiHLA antibodies prevalence was 13.6% for -A, 11.1% for -B and 6.2% for -Cw.
In spite of their lower frequency, some reports have been published concerning their association with AMR and impact on graft function and survival [8, 13, 14] . Besides, the recent development of the solid-phase immunoassays, in particular the single-antigen flow bead (SAFB) assays, allowed us to detect and properly identify anti-HLA-Cw antibodies. Tambur et al [15] compared virtual flow-cytometry cross-match to actual cross-match and described that 40% of the cases with a positive actual flow-cytometry cross-match and negative virtual crossmatch were explained by the presence of antiHLACw antibodies. Gilbert et al [7] compared two groups of sensitized recipients, one group with only classical HLA-A, -B, -DR, -DQ antibodies (n = 176) and the other group with classical plus HLA-C and/or -DP antibodies (n = 27). They concluded that there was a significant increase in the number of AMR among the group with pre-transplant anti-Cw and -DP antibodies. However, they did not distinguish between pre-transplant anti-DP or anti-Cw antibodies, and they speculated that anti-DP antibodies seemed to be involved more often in poorer graft outcomes. Ling et al [5] investigated the clinical outcomes in kidney transplant patients with isolated Cw-DSA. They identified eight patients with pre-transplant DSA antiHLA-Cw, exclusively. During a median 6 mo of follow-up (range 3-24 mo), patient and graft survival was 100% without any acute rejection occurring. In this group, all the patients had induction therapy with thymoglobulin or basiliximab and additionally all patients received intravenous immunoglobulin, similar to patients with positive FCXM and/or cPRA > 50%. Even so, the median time of follow up was relatively short and may have underestimated the incidence of rejection. Aubert et al [9] evaluated retrospectively 22 renal transplant recipients with isolated antiHLA-Cw DSA at day 0 of renal transplant, comparing them with 88 allosensitized patients with no preformed DSA (control group), and followed for a period of 1 year. Acute AMR was diagnosed in six patients (27.3%) in patients with DSA-Cw vs 9% in those without DSA. In this study, the patients with DSA antiHLA-Cw received less-intensive immunosuppression than the control group of sensitized patients, including ATG induction (only 59.1%), and this may probably be a plausible explanation for this high rate of AMR. However they alert for the necessity of screening pretransplant DSA HLA-Cw and subsequent modulation of immunosuppression in cases of positivity. More recently, Bachelet el al [10] investigated the clinical effect of DSA antiHLA-Cw and/or -DP, comparing 48 patients transplanted with isolated preformed DSA antiHLA-Cw and/or -DP with a group of HLA-sensitized recipients with no DSA (104 patients) and 47 kidney transplant recipients with preformed DSA antiHLA-A, -B, -DR, and/or -DQ. Two years after transplantation, the groups with DSA (both -Cw/-DP or -A/-B/-DR/-DQ) had similar incidence of AMR and graft survival (and worse than the group with no DSA), showing that preformed DSA anti-HLA-Cw and/or -DP were as deleterious as DSA anti-HLA -A/-B/-DR/-DQ. Our data reached similar results of these previous studies, confirming that DSA-Cw is associated with a similar incidence of AMR and impact on graft survival in comparison with "classical" DSA against class Ⅰ [9, 10] . We have also shown that patients that experienced AMR had a significant lower kidney graft survival in comparison to patients who did not (respectively, 75% vs 100%, Logrank P = 0.005), with the sole independent predictor of AMR incidence being DSA strength. The negative impact of DSA for AMR occurrence and adverse results on kidney graft survival has been previously established [2] . Lefaucheur et al [16] stated that it is the occurrence of AMR associated with DSA that has impact on graft survival, since graft survival of DSA-positive patients, in the absence of AMR, is the same as DSA-negative patients. Furthermore, DSA characteristics as number, class or strength may have a negative impact on graft outcomes [1, [17] [18] [19] . Malheiro et al [20] showed that DSA strength (MFI) had a reasonable ability to predict AMR occurrence, with no cases of AMR occurring below a MFI < 3000. However when the MFI values increased from this value, also did the risk of AMR. Again, Aubert et al [9] in their retrospective study with 22 renal transplant recipients with preformed isolated antiHLA-Cw DSA, showed that the level of DSA at day 0 was predictive for AMR: Measurement of MFI was 4966 (978-17941) in the AMR group and 981 (530-8012) in the group of patients without AMR (P = 0.017). This study has limitations. First, the small number of patients in the cohort limits our ability to generalize the results. Second, follow-up time difference may have limited the comparative analysis of graft survival according with DSA HLA loci. Contrarily, AMR incidence was not influenced by it, since it was analyzed at 1-year post-transplant. Third, there was no protocol biopsies performed in our patients and it is an important tool for HLA incompatible kidney transplantation [21, 22] . Lastly, the limitations of SAB assay are well established and their reported MFI values should be considered for analyzing our results [23] . In summary, our data show that preformed DSA antiHLA-Cw exerts a deleterious effect in presensitized kidney transplant recipients that is similar when compared to antiHLA antibodies against other class I locus (antiHLA-A or -B). Also, the association between AMR occurrence and reduced graft survival is clear, with DSA strength being predictive of rejection. Therefore, HLA-C typing and respective antibody identification will benefit sensitized patients during organ allocation.
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Background
Classically, antibodies to major human leukocyte antigen (HLA) Class I (A and B) and Class Ⅱ (DR and DQ) antigens are considered to be responsible for most cases of AMR. Compared to other class Ⅰ antiHLA antibodies, antiHLA-Cw are considered less immunogenic.
